8-K current report · filed Aug 18, 2026

Biomarin Pharmaceutical Inc (BMRN) 8-K Current Report: August 18, 2026

Item 1.01Item EX-99.1Item 7.01BMRN overview

Short answer

Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on August 18, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). BioMarin acquiring Dutch rare-disease developer Alesta for $275 million upfront, cash-free and debt-free.

Biomarin Pharmaceutical Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • BioMarin acquiring Dutch rare-disease developer Alesta for $275 million upfront, cash-free and debt-free
  • Additional payments up to $215 million tied to development milestones, creating contingent acquisition consideration
  • Alesta adds novel oral small-molecule therapies targeting underserved rare diseases
  • Closing expected in Q3 2026, subject to asset transfers, legal clearance and customary conditions
  • Transaction could expand BioMarin’s rare-disease pipeline, but milestone payments depend on development progress

Item 7.01 · Regulation FD Disclosure

  • BioMarin announced execution of a Purchase Agreement on August 18, 2026
  • The transaction announcement may affect strategic direction and valuation, with deal terms in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Acquisition adds ALE1, a Phase 1/2a oral HPP candidate with potential to become the first oral therapy for the disease
  • $275 million upfront payment, plus up to $215 million tied to development and regulatory milestones
  • BioMarin funding from cash on hand, with modest 2026 dilution excluding upfront consideration
  • Closing expected this quarter, subject to customary conditions and Alesta’s spinout of non-ALE1 assets
  • Strategic expansion into larger rare-disease markets, but value depends on clinical and regulatory success

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Biomarin Pharmaceutical Inc 8-K filings

Get the next BMRN 8-K as it lands

Follow BMRN for push alerts, or ask the research agent what this filing means.